KdT Ventures is the standard for early-stage science venture investing, helping founders and their companies re-architect the world at a molecular level.
Managed by Cain McClary MD, and Mack Healy JD, the team uses its expertise across multiple disciplines and industries to invest in and support meaningful teams applying computation to chemical and biological systems.
Here at KdT we believe the greatest advancements of our lifetime will be the result of reprogramming chemistry and biology using creative technology platforms. Check out some of the ways our portfolio companies are making that happen in our news below.